Review of Exercise and the Risk of Benign Prostatic Hyperplasia

被引:2
作者
Sea, Jason
Poon, Kenneth S. [1 ]
McVary, Kevin T. [2 ]
机构
[1] Univ British Columbia, Dept Urol Sci, Gordon & Leslie Diamond Hlth Care Ctr, Vancouver, BC V5Z 1M9, Canada
[2] Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
benign prostatic hyperplasia; lower urinary tract symptoms; exercise; physical activity; lifestyle; URINARY-TRACT SYMPTOMS; LIFE-STYLE RECOMMENDATIONS; HEART-ASSOCIATION COUNCIL; 3RD NATIONAL-HEALTH; PHYSICAL-ACTIVITY; METABOLIC SYNDROME; RESISTANCE EXERCISE; AMERICAN-COLLEGE; PUBLIC-HEALTH; CARDIOVASCULAR-DISEASE;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
It has been long appreciated that a healthy lifestyle plays a critical role in cardiovascular health. It is now apparent that the same is true in the development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Since 1995, 14 studies have been identified that investigate the clinical relationship between exercise and BPH/LUTS. No randomized controlled trials have been performed, but useful prospective cohort data originating from recent publications on the medical treatment of BPH and prevention of prostate cancer are available. Most of the literature supports a clinically significant, independent, and strong inverse relationship between exercise and the development of BPH/LUTS. Several mechanisms for this relationship have been proposed, including decreased sympathetic tone, avoidance of metabolic syndrome, and reduced oxidative damage to the prostate.
引用
收藏
页码:82 / 90
页数:9
相关论文
共 50 条
  • [21] Benign prostatic hyperplasia
    Chughtai, Bilal
    Forde, James C.
    Thomas, Dominique Dana Marie
    Laor, Leanna
    Hossack, Tania
    Woo, Henry H.
    Te, Alexis E.
    Kaplan, Steven A.
    NATURE REVIEWS DISEASE PRIMERS, 2016, 2 : 1 - 15
  • [22] Benign prostatic hyperplasia
    Parnham, Arie
    Haq, Ahsanul
    JOURNAL OF CLINICAL UROLOGY, 2013, 6 (01) : 24 - 31
  • [23] Inflammatory mediators in the development and progression of benign prostatic hyperplasia
    De Nunzio, Cosimo
    Presicce, Fabrizio
    Tubaro, Andrea
    NATURE REVIEWS UROLOGY, 2016, 13 (10) : 613 - 626
  • [24] Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia
    Hammarsten, J
    Högstedt, B
    EUROPEAN UROLOGY, 2001, 39 (02) : 151 - 158
  • [25] Behaviour modification and benign prostatic hyperplasia: replacement for medications
    Yap, Tet
    Emberton, Mark
    CURRENT OPINION IN UROLOGY, 2010, 20 (01) : 20 - 27
  • [26] Association between prostatic resistive index and cardiovascular risk factors in patients with benign prostatic hyperplasia
    Baykam, Mehmet Murat
    Aktas, Binhan Kagan
    Bulut, Suleyman
    Ozden, Cuneyt
    Deren, Tagmac
    Tagci, Suleyman
    Gokkaya, Cevdet Serkan
    Memis, Ali
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2015, 31 (04) : 194 - 198
  • [27] Silodosin in the treatment of benign prostatic hyperplasia
    Rossi, Maxime
    Roumeguere, Thierry
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 291 - 297
  • [28] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Kuczyk, M. A.
    Herrmann, T. R. W.
    UROLOGE, 2009, 48 (11): : 1365 - 1375
  • [29] Endocrine control of benign prostatic hyperplasia
    La Vignera, S.
    Condorelli, R. A.
    Russo, G. I.
    Morgia, G.
    Calogero, A. E.
    ANDROLOGY, 2016, 4 (03) : 404 - 411
  • [30] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Martinelli, E.
    UROLOGE, 2016, 55 (01): : 81 - 94